Revolution Medicines CFO Jack Anders Sells $6.72M of Stock
Jack Anders, CFO, sold 35,750 shares of Revolution Medicines, Inc. at $181.04 to $192.84 a share (average $188.10) in 11 transactions, worth $6.72M in total on Nov 11, 2026. Shares held after the trade: 119,216 (-7.7%).
Revolution Medicines reported its first product revenue of $197.6 million for the quarter ended September 30, 2026, following the commercialization of RASONQUE® (daraxonrasib). The company significantly strengthened its balance sheet, ending the period with approximately $3.65 billion in cash and marketable securities, though it continues to operate with a substantial accumulated deficit of $4.37 billion.
Revolution Medicines reported financial results for the third quarter of 2026, highlighted by the U.S. commercial launch of RASONQUE (daraxonrasib) for metastatic pancreatic cancer. The product generated $197.6 million in net revenue during its first five weeks on the market, with over 5,000 unique patients treated. The company also received a positive CHMP opinion for the drug in the European Union.
Term
Q3 2026
“The U.S. approval and launch of RASONQUE marked a monumental step forward for eligible patients with pancreatic cancer and a transformational quarter for Revolution Medicines, and the CHMP opinion sets the stage for potential approval in the European Union.”
Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines
Revolution Medicines Insider Anthony Mancini Sells $432K of Stock
Anthony Mancini sold 2,310 shares of Revolution Medicines, Inc. at $186.99 a share, worth $432K in total on Oct 26, 2026. Shares held after the trade: 39,765 (-5.5%).